In summary, vascular-targeted therapy with endostar could prolong the DFS of patients with complete resectable NSCLC in stage IIIA and significantly extended the DFS of NSCLC patients with high expression of VEGF, but did not show benefits in OS for stage IB−IIIA. This evidence concerns the gene VEGFA and non-small cell lung carcinoma.